Introduction
Glioblastoma multiforme (GBM) is the most malignant astrocytic tumor found in the central nervous system, and causes severe neurological complication and devastating consequences for the patient. The median survival of patients with this tumor is less than 20 months, compared to more than 5 years for low grade (grade I or II) astrocytoma (Ushio, 1991) . This dierence of prognosis re¯ects the biological characteristics of the tumors and is also attributed to their genetic abnormalities. Recent cytogenetic, molecular, and biochemical analyses have revealed that the generation and progression of astrocytic tumors are induced by the accumulation of multiple but relatively consistent genetic alterations. These alterations include the activation of proto-oncogenes and the functional loss of tumor suppressor genes. A loss of heterozygosity (LOH) on chromosome 10, mutations in the p53 gene, homozygous deletion of the p15 and p16 genes and ampli®cations of the epidermal growth factor receptor (EGFR) gene are genetic changes frequently found in astrocytomas (Reifenberger et al., 1996; Li et al., 1995; Sonoda et al., 1995; Fleming et al., 1992; Collins and James, 1993) . Mutations in the p53 gene are frequently found in the early stage of astrocytomas (Rasheed et al., 1994; Sonoda et al., 1996) , whereas the LOH of chromosome 10 is a rare event in low-grade astrocytomas and almost exclusively occurs in high-grade astrocytomas . Almost 80% of GBM cases exhibit loss of alleles on chromosome 10. A great deal of interest has therefore been focused on the identi®cation of a putative tumor suppressor gene or genes within the region of LOH, because the alteration of such a gene may be closely involved in the malignant progression from low-grade astrocytoma to GBM.
Allelic losses of chromosome 10 in GBM are generally extensive, and a complete copy of the chromosome is frequently lost (Fults et al., 1990) . Therefore, it has not been easy to identify the common deletion region. Deletion mapping studies performed in various laboratories using samples with a partial loss of chromosome 10 revealed that up to three distinct deletion regions are present in the chromosome: 10pter-p13, 10q23-24, and 10q24-qter (Rasheed et al., 1992; Sonoda et al., 1996; Karlbom et al., 1993) . These data indicated that multiple genes on chromosome 10 are associated with the genesis and progression of malignant astrocytomas. One of the candidate tumor suppressor genes, named the PTEN/MMAC1 gene, was recently identi®ed on 10q23.1 and was found to be frequently mutated in various cancers including astrocytoma, breast cancer and prostate cancer (Li et al., 1997; Steck et al., 1997) . However, another two or even more genes critical to the development of malignant astrocytoma are expected to exist on chromosome 10.
In the present study, we performed a detailed LOH analysis of chromosome 10q in anaplastic astrocytoma and GBM using a¯uorescence-based, semi-automated polymorphism detection system (FSPDS) (Reed et al., 1994) . We determined a speci®c and frequent deletion in the region between D10S192 and D10S566 localized at 10q25.1, which is not the region where the PTEN/ MMAC1 gene was mapped. We also identi®ed a human gene with strong homology to the Drosophila neuralized (D-neu) gene within this region. D-neu belongs to a group of genes associated with neurogenesis in Drosophila, and its loss-of-function mutation was shown to lead to an over-production of primitive neuronal cells (Boulianne et al., 1991; Price et al., 1993) . The human homolog of D-neu, designated as hneu, may therefore be a good candidate for the gene involved in the genesis of malignant astrocytoma.
Results

Determination of the speci®c LOH region on chromosome 10q in malignant glioma
To identify the speci®c LOH regions in chromosome 10q in high-grade astrocytomas including anaplastic astrocytoma [AA] (grade III) and GBM (grade IV), we performed analyses using the FSPDS. The FSPDS allows the automatic scoring of the allele size and peak height with the use of the GENES-CAN TM 672 and Genotyper TM software programs, and we were therefore able to objectively evaluate the data. Tumor DNA was extracted from the frozen tissue sections, and the proportion of tumor cells in each area was assessed by a histological examination of sequential sections stained with hematoxylin and eosin (H-E). We selected the sections in which more than 90% of cells were tumor cells for DNA extraction.
In an earlier phase of our work, we examined pairs of normal leukocyte DNA and tumor DNA from 23 malignant astrocytoma patients (12 GBM and 11 AA), with eight microsatellite markers spanning a large portion of chromosome 10q (10q21-telomere), from locus D10S201-D10S212 (Figure 1) . Eight of the 12 GBM patients (67%) and three of the 11 AA patients (25%) exhibited LOH aecting at least one locus. Figure 2 shows representative results obtained by FSPDS analysis. As summarized in Figure 1 , the deletions were frequently observed at two separate loci, D10S205 (7/11) and D10S212 (5/9), in the GBM patients. Four loci (D10S597, D10S545, D10S587, and D10S186) between D10S205 and D10S212 showed a much lower LOH rate in the GBM patients. This ®nding suggested that at least two candidate loci for the putative tumor suppressor genes for GBM exist at a proximal region around D10S205 and a telomeric region around D10S212 in chromosome 10q.
Tumor GB4 demonstrated LOH on D10S205, whereas it showed conserved heterozygosity on loci D10S200 and D10S597 (Figure 2b ). Accordingly, we focused on the identi®cation of a minimal interstitial LOH region around D10S205 rather than a telomeric region around D10S212 in this study. We extended our analysis to 44 malignant astrocytomas (20 GBM and 24 AA) and added four microsatellite markers (D10S603, D10S222, D10S192, and D10S566) near D10S205 for further detailed deletion mapping. The results are shown in Figure 3 . Ten of the 20 GBM patients and seven of the 24 AA patients showed LOH aecting at least one locus in this region. Tumor GB17 displayed retention of heterozygosity on loci D10S603 and D10S222, whereas it showed LOH on D10S192 and D10S566 (Figure 4a ). GB15 also demonstrated loss on D10S192 and conserved heterozygosity on D10S222 (Figure 4b ). GB4, which exhibited LOH on loci D10S205 and D10S566, showed retention of heterozygosity on D10S192. Furthermore, ®ve anaplastic astrocytomas (AA10, AA11, AA12, AA16 and AA20) were shown to have an allelic loss in a small region¯anked by D10S192 and D10S566. These eight H Nakamura et al informative cases allowed us to conclude that the deletion or translocational event commonly occurred at the region between D10S192 and D10S566.
Identi®cation of h-neu gene on the frequent LOH region
We performed detailed mapping of the microsatellite markers used for the LOH study by screening the Genebridge 4 radiation hybrid (RH) panel. The results of the RH mapping are illustrated in Figure 5 . The distance between D10S192 and D10S566 was 11.8 cR, and we looked for a candidate tumor suppressor gene within this region. We performed a database (UniGene) analysis to ®nd EST clones mapped on the 10q24-25 and determined their precise localization by the RH mapping procedure. In this analysis, we identi®ed the EST clone H51423 residing on chromosome 10q24-25, and found that the amino acid sequence deduced from one of the open reading frames of the H51423 clone showed a strong homology with Drosophila neuralized (D-neu) protein.
A BLASTn search of the EST H51423 sequence against dbEST identi®ed two potential overlapping ESTs (H82634 and H82635). Based on the sequences of these three ESTs, we performed a two-step polymerase chain reaction (PCR) to clone the full-length cDNA ( Figure 6 ). We identi®ed a 1803-bp cDNA which contains an open reading frame encoding a polypeptide of 557 amino acids (GenBank accession no. U87864).
The nucleotide sequence was con®rmed by sequencing several clones that were generated by independent PCR to avoid PCR artifact. No dierences in the nucleotide sequence of the various clones were found. A BLASTp search of the non-redundant protein database revealed that the predicted amino acid sequences of the cloned cDNA have high similarity to a D-neu (accession #L12218, smallest sum probability P(n)=5.6e-77) and C. elegans neuralized homolog [C-neu] (accession #U40945, P(n)=3.1e-79) ( Figure 7 ). This gene is the ®rst vertebrate homolog of the neuralized gene, and we designated it as h-neu (human neuralized). The overall amino acid sequence of the h-neu protein has 30% identity and 32% identity with D-neu and C-neu, respectively. These three proteins all contain C 3 HC 4 -type RING zinc-®nger domains at their carboxy-terminus (Figure 8a,c) . Amino acid sequences of the RING zinc-®nger domain of h-neu are highly conserved with those of D-neu (41%) and C-neu (54%). All three proteins contain a second homology region, consisting of two repeat units each about 160 amino acids in length (Figure 8a,b) . We designated this repeat unit as NHR (neuralized homology repeat). To date, our database searches have failed to identify other proteins with NHR domains. The opa repeats and nuclear localization signal found in D-neu were not identi®ed in h-neu.
We determined the precise chromosomal localization of the h-neu gene by using the Genebridge 4 RH panel.
Comparison with the human chromosomal content of the hybrids, as determined by the Whitehead Institute/ MIT Center for Genome Research, localized the h-neu gene to chromosome 10q and placed it 0.6 cR from D10S540, which was mapped at the frequent LOH region between D10S192 and D10S566 ( Figure 5 ). Our uorescence in situ hybridization (FISH) analysis also localized this gene to 10q25.1 (data not shown).
Northern blot analysis of h-neu gene in malignant astrocytoma tissues and glioma cell lines
To investigate the expression of h-neu transcript, samples from three normal brain tissues, four astrocytoma tissues (one AA [grade III] and three GBM [grade IV] and ten glioma (astrocytoma) cell lines (NP1, NP2, 105MG, U251MG, U373MG, RBR17T, SF126, U138MG, A172, Hs683) were analysed by Northern blot hybridization. Nylon membranes were hybridized successively with radio- showed LOH on D10S205 (imbalance factor 420) and retention of heterozygosity on D10S200 and D10S597 (imbalance factors=1.41 and 1.15) h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al labeled probes for h-neu and b-actin ( Figure 9 ). The hneu transcript, which was 4.2 kb in size, was expressed in the normal brain tissues and an anaplastic astrocytoma tissue, whereas it was expressed at very low levels or not detectable in the GBM tissues and glioma cell lines examined.
Mutation analysis of the h-neu gene in malignant astrocytoma
To investigate mutations of the h-neu gene in malignant astrocytic tumor, we performed DNA sequence analysis of the RT ± PCR products corresponding to the entire coding sequences of h-neu transcript. As shown in the Northern blot analysis, levels of h-neu transcript expression tended to be high in normal brain tissue but very low in GBM tissues. Therefore, sensitive RT ± PCR reactions might have dominantly ampli®ed the h-neu transcript derived from migrating normal cells instead of tumor cells if we had analysed clinical tumor tissue samples. To avoid this problem, we performed the mutation analysis of the hneu gene in established glioma cell lines.
Although the h-neu transcript was eciently ampli®ed by RT ± PCR from normal brain tissues and other neuroectodermal tumor cell lines such as medulloblastoma, most of the glioma cell lines examined except for U87MG showed very little or no RT ± PCR product corresponding to h-neu cDNA after 30 cycles. Representative RT ± PCR results are demonstrated in Figure 10a . However, reampli®cation for additional cycles or collection of the several initial RT ± PCR products yielded sucient product for sequencing h-neu transcripts from seven glioma cell lines (U87MG, U251MG, U138MG, SF126, U373MG, U105MG) out of 12 cell lines examined. Direct DNA sequencing analysis showed that six of the seven glioma cell lines were found to have identical sequence to the h-neu sequences derived from normal human tissue. However, one of the cell lines, U251MG, was shown to have a G to A substitution at codon 253 (GGC?AGC) that resulted in an amino acid change from glycine to serine (Figure 10b ). To ensure that the sequence change was not an artifact of direct PCR sequencing, enzyme digestion of the RT ± PCR product containing codon 253 was performed (Figure 10c ). Since the presumptive mutation created a new PvuII site in addition to the site normally present at codon 404, the 1071 bp RT ± PCR product from U251MG cells was cleaved with PvuII to produce the expected 153-, 457-and 461-bp subfragments ( Figure  10d ). In contrast, the 1071-bp product from the RNA of normal tissues was cleaved with PvuII to generate Figure 4 Detection of LOH in glioblastomas GB17 and GB15 by FSPDS analysis. N and T indicate normal and tumor DNA, respectively. Fluorescently-labeled PCR products of microsatellite marker loci were electrophoresed and analysed by the GENES-CAN TM 672 and Genotyper TM software programs. Each panel shows the peaks illustrating the relative¯uorescence intensity of the detected fragments. (a) Tumor GB17 demonstrated LOH on locus D10S566 (imbalance factor 420) and D10S192 (imbalance factor 420) and retention of heterozygosity on D10S222 (imbalance factor=1.12) and D10S603 (imbalance factor=1.05). (b) Tumor GB15 showed LOH on locus D10S192 (imbalance factor=3.2) and retention of heterozygosity on D10S222 (imbalance factor=1.15) h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al 610-and 461-bp fragments. Both direct DNA sequence and restriction length analyses revealed that U251MG expressed only the mutated h-neu transcript and not the normal transcript, which suggested that U251MG may have had a loss of a normal allele of the h-neu gene. The lack of normal DNA from the patient who had the U251MG tumor cell did not allow us to determine whether the G to A substitution at codon 253 was a constitutional change. However, since this substitution has not been identi®ed in any of the normal tissues and other cell lines we have examined to date, it is most likely to be a mutation or rare polymorphism.
Discussion
In our initial study of 23 malignant astrocytomas (12 GBM and 11 AA) utilizing eight loci spanning 10q21-telomere, we identi®ed two commonly deleted regions in chromosome 10q. We then performed detailed deletion mapping around the most frequently deleted locus, D10S205, using 44 malignant astrocytoma samples (20 GBM and 24 AA) to identify the areas where tumor suppressor genes may be located. The deletion mapping study revealed that 50% (10/20) of the GBM patients and 33% (8/24) of the AA patients displayed allelic deletions in the region between D10S192 and D10S566 localized at 10q25.1. One of the major problems encountered in determining the common deletion regions in astrocytic tumors has been the PCR signal generated by contaminating nonneoplastic cells in the tumor samples. Since malignant astrocytoma cells tend to aggressively invade into the adjacent normal brain, the tumor tissues generally contain a considerable number of nonneoplastic cells. We tried to circumvent this problem by using frozen tissue sections selected under direct histopathologic examination and utilized the sections in which more than 90% of cells were tumor cells for the DNA extraction. However, GBM tissues are considered to be composed of mixed tumor cell population which is genetically heterogeneous. Therefore, assessment of LOH in the tumors was carefully performed in this study, and the cuto point was de®ned as imbalance factor 41.5, which re¯ect an allele reduction of one-third or more in tumor DNA.
Previous reports demonstrated that malignant astrocytomas have at least three commonly deleted regions on chromosome 10, i.e. 10pter-p13, 10q23-24, and 10q24-qter (Sonoda et al., 1996) . A loss of the 10q24-qter (or 10q25) region has been most frequently described (Rasheed et al., 1992; Karlbom et al., 1993; Albarosa et al., 1996) . Our present study using FSPDS with highly polymorphic microsatellite markers provided further evidence for the presence of a tumor suppressor locus at 10q25. One of the candidate genes, PTEN/MMAC1, has been recently identi®ed on chromosome 10q and found to be mutated in not only astrocytomas but also various advanced cancers including prostate, renal and breast carcinomas (Li et al., 1997; Steck et al., 1997) . However, the PTEN/ MMAC1 gene was mapped between D10S215 and D10S541 localized at 10q23.3, which is distant from the region we determined. Accordingly, another candidate tumor suppressor gene for the malignant Figure 5 Radiation hybrid mapping of microsatellite markers in chromosome 10q24-25. The interlocus distances for these marker loci are shown on the left. The common deletion region spanning from D10S192 to D10S566 are indicated by the dotted line on the right. The h-neu gene was mapped at 0.6 cR from D10S540 Figure 6 Cloning strategy of the h-neu gene. P1, P2, P3 and P4 primers were designed based on the sequence information of the EST clones H82634, H51423 and H82635. Ampli®cation of the 5' region (region A) and 3' region (region B) were carried out by the two-step PCR procedure using the human fetal brain cDNA library (Clontech). For ampli®cation of the remaining 3' region (region C), P5 primer was used for the ®rst PCR, and P6 and T7 primers were used for the second PCR h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al progression of astrocytic tumors, distinct from PTEN/ MMAC1, is thought to exist at the 10q25 region.
In the process of verifying the precise location of various EST clones residing around 10q24-25, we identi®ed a novel cDNA obtained by the two-step PCR procedure based on sequence information of the three overlapping ESTs on the region between D10S192 and D10S566. The predicted 557 amino acid coding sequence of this gene, h-neu, was highly homologous to proteins encoded by the Drosophila neuralized (D-neu) gene. Northern blot and RT ± PCR analyses demonstrated that the h-neu gene was markedly reduced or undetectable in GBM tissues and most glioma cell lines whereas it was found to be expressed in normal adult brain tissues and other types of neuroectodermal tumors. Furthermore, one of the glioma cell lines, U251MG, was found to have a nucleotide substitution which resulted in an amino acid alteration at codon 253. These results suggested that epigenetic and/or genetic alterations which suppress the function of h-neu may occur in malignant astrocytoma cells.
D-neu belongs to a group of neurogenic genes which are involved in the determination of cell fate in the neurogenic region of the Drosophila embryo. This group of neurogenic genes includes Notch (N), Delta (Dl), Enhancer of split [E(spl)], neuralized (neu), mastermind (mam), big brain (bib) and almondex (amx) (Preiss et al., 1988; Corbin et al., 1991; Hartenstein et al., 1992) . During the development of the central nervous system in Drosophila, a cell committed to be a neuronal precursor inhibits neighboring cells from becoming neurons, thereby obliging them to become epidermal cells. This process, which is called lateral inhibition, is considered to be regulated by the neurogenic genes. Mutation of the D-neu gene causes a defect in the process of lateral inhibition, resulting in the hyperplasia of primitive neural tissue, which is a common phenotype shared with other neurogenic mutants. These observations may support the hypothesis that the h-neu gene plays a role in the determination of cell fate in the human central nervous system. It is thus conceivable that a loss-of-function of the h-neu gene (Higgins et al., 1996) . Amino acid residues on D-neu and C-neu identical to h-neu protein in the same position are indicated by shading, with the corresponding consensus sequence for all three proteins written beneath in bold. The NHR domains and RING zinc-®nger motif which are conserved in all three proteins are boxed. Motifs of D-neu protein are indicated as follows: a putative nuclear localization signal (----), opa repeats (-Ð -Ð) and helix ± turn ± helix domains (ÐÐ) h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al may lead to the development of neuroectodermal tumors.
The most extensive homology among h-neu, D-neu and C-neu is in the carboxy-terminal RING zinc-®nger domain which is a potential DNA-binding domain. Various proteins which contain the RING zinc-®nger domain have been identi®ed and characterized (Lovering et al., 1993) . Among the vertebrate genes containing the RING zinc-®nger motif, mel-18, a polycomb group-related gene, was shown to have tumor suppressing activity (Kanno et al., 1995) , and BRCA1, a breast and ovarian cancer susceptibility (Miki et al., 1994) . Moreover, some of the RING zinc-®nger proteins including bmi-1 (Alkema et al., 1997) , CBL2 (Savage et al., 1991) , ret (Takahashi et al., 1988) , and PML1 (Doucas et al., 1993) are proto-oncogene products or are associated with oncogenesis. Recent reports have revealed that the inhibitor-of-apoptosis (IAP) family of proteins have a carboxy-terminal RING zinc-®nger domain whose amino acid sequences are highly similar to that of the neuralized protein (Figure 8c ). The IAP family proteins were found to have an evolutionarily conserved role in negatively regulating apoptosis in animals ranging from Drosophila to humans (Duckett et al., 1996; Hay et al., 1995) . These lines of evidence suggest that proteins possessing the RING zinc-®nger domains are heavily associated with cell fate and contribute to development, cell growth and apoptosis.
In conclusion, we have identi®ed the h-neu gene, which is the ®rst vertebrate homolog of D-neu and Cneu in the LOH region at 10q25.1 to be studied in malignant astrocytomas. We found that the h-neu expression was markedly reduced in human GBM tissues and glioma cell lines. Furthermore we showed that U251MG cell had a G to A substitution, leading to a glycine to serine substitution at codon 253 of hneu. These ®ndings together with the evidence that the functional mutation of D-neu causes hyperplasia of the neural tissue in Drosophila imply that h-neu is a h-neu β-actin Figure 9 Expression of h-neu transcript in three human normal brain tissues (normal one, two and three) and four human astrocytoma tissues (one anaplastic astrocytoma [AA1] and four glioblastoma multiformes [GB1, GB3, GB4] and ten glioma cell lines whose names are written on the top of the panel. Northern blot hybridization was performed using a speci®c cDNA probe of h-neu and a human b-actin. Each lane was loaded with 10 mg of total RNA. A 4.2-kbp transcript for the h-neu gene, which is indicated by an arrow, was detected in three normal brain tissues and an anaplastic astrocytoma tissue Figure 10 Mutation analysis of h-neu transcript in glioma cell lines. (a) Ampli®cation of h-neu transcript by RT ± PCR using total RNA extracted from a human normal brain tissue (normal), Med-3 human medulloblastoma cell line and seven glioma cell lines whose names are written on the top of the panel. The h-neu transcript was ampli®ed with a set of primers neuS-13 and neuAS-stop. The GAPDH transcript was also ampli®ed using primers GAPDHsens and GAPDHanti to ensure the successful completion of cDNA synthesis and PCR reaction. h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al candidate tumor suppressor gene. Detailed mutation analysis after the determination of its genomic structure and introduction of wild-type copies of the h-neu gene into glioma cells will be required for a ®nal assessment of the involvement of h-neu in the development and growth regulation of malignant astrocytomas.
Materials and methods
Tissue specimens and genomic DNA extraction
Tumor tissues and matched normal blood samples were obtained from 44 patients who underwent the therapeutic removal of a primary brain tumor at Kumamoto University or Nakamura Memorial Hospital. The histopathological examination, which was performed according to the WHO (World Health Organization) criteria, revealed that 20 samples were as GBM and 24 samples were as AA. Tumor tissues were frozen at the time of tissue removal and stored frozen for 0 ± 3 years at 7808C before the isolation of DNA. Genomic DNA was extracted from the tumor tissue sections, which were con®rmed to contain more than 90% tumor cells by the histological examination of sequential sections. In this examination, 10 ± 20 slices of 6 mm sections were cut from frozen tissue mounted in Tissue Tek II (Lab-Tek Products, Naperville, IL) and suspended in 100 ml of digestion buer (50 mM Tris, 5 mM ethylenediaminetetraacetic acid (EDTA), 300 mg/ml proteinase K, pH 8). The samples were then incubated at 568C for 6 h. The DNA was extracted using phenol and chloroform (1 : 1, three times), precipitated in 70% ethanol, and dried in a Speed-Vac Concentrator (Savant Instruments Inc, Framingdale, NY). The DNA pellets were resuspended in distilled water and then subjected to PCR ampli®cation. Usually, 0.5 ± 1 mg genomic DNA could be extracted from 10 ± 20 slices of 6 mm frozen sections, and this was sucient for the microsatellite analysis. Normal (leukocyte) DNA was prepared using the same method of tumor DNA extraction.
PCR
Tumor DNAs were investigated for LOH using 12 polymorphic microsatellite markers. The sequences of the primers used for this analysis are listed in Table 1 . PCR forward primers were labeled with 6-FAM, HEX or TET phosphoramidites (Applied Biosystems, Foster, CA). PCR reactions were performed in a 25 ml volume using rTth DNA polymerase per manufacturer instructions (Applied Biosystems) with a Perkin-Elmer Cetus Gene Amp PCR system 9600 (Norwalk, CT) for 30 cycles of optimized PCR conditions by varying both the annealing and denaturing temperatures. PCR products were electrophoresed on 2% agarose gels for the con®rmation of the successful PCR ampli®cation.
FSPDS analysis of PCR products
The PCR products (0.5 ml) were applied on 6% acrylamide gels (Bio-Rad Laboratories, Richmond, CA) including 7 M urea (Nacalai Tesque, Kyoto, Japan), with 4 ml of formamide and 1 ml of the internal lane size standard GENESCAN-500 TAMRA (Applied Biosystems) designed for sizing DNA fragments in the 35 ± 500 bp range. Electrophoresis was carried out for 6 h using a model 373A Sequencer (Applied Biosystems). In heterozygous cases, two peaks were obtained according to the dierent migration patterns of both alleles. Allelic loss was determined semiquantitatively using the GENES-CAN TM 672 and Genotyper TM software programs (Applied Biosystems). Peak areas representing the alleles of both the tumor and corresponding leukocyte DNA were compared. The ratio calculated for both alleles in the tumor DNA (allele retained/allele lost) was divided by the corresponding ratio found in the leukocyte DNA. The resulting values (imbalance factor) of 41.5, which re¯ect an allele reduction of one-third or more in tumor DNA, were de®ned as the LOH cuto point as de®ned elsewhere (Frank et al., 1997) .
RH mapping of microsatellite markers and EST searching
The microsatellite markers and EST clones were mapped using the GeneBridge 4 RH Screening Panel (Research Genetics, Huntsville, AL). The PCR reaction was performed using the set of primers for each marker under the conditions previously described (Makino et al., 1997) . The PCR results were sent to Whitehead Institute for Biomedical Research/MIT Center via the internet (http:// www-genome.wi.mit.edu/) for determining the positions of the markers relative to the RH map of the human genome (Hudson et al., 1995) . The EST clones localized on 10q24-25 or near the region between D10S192 and D10S566 were searched by screening the database of the expressed sequence tags (dbEST) and the unique human gene sequence collection (UniGene) network service at the National Center for Biotechnology Information (NCBI).
PCR-based full-length cDNA cloning
The method for PCR-based full-length cDNA cloning from EST clones was reported previously (Makino et al., 1997) . For ampli®cation of the 5' region, the ®rst PCR was performed using only a primer P1 (5'-AGCACTGCCG-GACAGTGCTTCTG-3') to amplify single-strand cDNA from a human fetal brain cDNA library (Clontech, Palo Alto, CA) in a 25 ml reaction volume for 50 cycles. The h-neu: a candidate tumor suppressor at 10q25 H Nakamura et al ®rst PCR product was used as a template in the second run, where P2 (5'-GTGGTGGCATCGGTGAGAAGTGA-3') and T3 (5'-ATTAACCCTCACTAAAG-3') were utilized as primers to amplify the 5' region cDNA. Ampli®cations of the 3' regions were also performed by the same two-step PCR procedure. For the 3' region ampli®cation, P3 (5'-GGCCGTGTCTTCCACCGCATCAA-3') was used for the ®rst round PCR, and P4 (5'-CTCGGCTGTTATGCT-GTTCTTCA-3') and T7 (5'-AATACGACTCACTATAG-3') were used for the second round PCR. For ampli®cation of the remaining 3' region, P5 (5'-TCGTCAAGGT-CACGCG CTCGGGT-3') was used for the ®rst PCR, and P6 (5'-TGTCGTTCGGCGTC ACCACGTGC-3') and T7 were used for the second PCR. The PCR fragments were ligated into a pCRII TA cloning vector and sequenced. All PCR procedures were performed by using rTth DNA polymerase (Perkin Elmer), which has proofreading activity. The DNA sequencing of plasmid DNAs was performed by standard protocols. The nucleotide sequence was con®rmed by sequencing several clones (more than three) that were generated by independent PCR to avoid errors introduced during the PCR reaction. The DNA and protein sequences were compared by the basic local alignment search tool (BLAST) network service at NCBI.
RH mapping of h-neu gene
PCR was performed to detect h-neu sequences in the Genebridge 4 RH Screening Panel using a set of primers (neuS-16: 5'-GTGGACGCCTCGCAGCCGCTTTG-3' and neuAS-int1: 5'-ATGAGCCTGGAGGAAGGGGAGC-3') which were designed based on a partial genomic sequence of the h-neu gene. The primers were expected to amplify a 166-bp PCR product from human genomic DNA as a template. The PCR results of the RH Panel were sent to the Whitehead Institute/MIT Center for Genome Research via the internet for mapping the gene as described above.
Northern blot analysis
Total RNA was prepared from four human malignant glioma tissues (one AA [grade III] and three GBM [grade IV]) and ten human glioma cell lines by the acidguanidinium thiocyanate-phenol-chloroform method. We also extracted total RNA from three samples of normal human brain tissues obtained during surgical lobectomies for management of cerebral traumas and cerebrovascular diseases. The extracted RNAs were ®rst analysed by agarose electrophoresis and ethidium bromide staining to ascertain their quality. Total RNA was size fractionated on a denaturing 6% formaldehyde-1% agarose gel and transferred to a Nylon membrane (Hybond TM -N+, Amersham Corp, Arlington Heights, IL). Hybridization was carried out overnight at 428C with an a-32 P-dCTPlabeled probe, 50 mM HEPES (pH7), 0.75 M NaCl, 50% formamide, 3.5% SDS, 56Denhart's, 2 mM EDTA, 0.1% SDS, and 200 mg/ml salmon sperm DNA. Filters were washed twice in the same buer, 26SSC, 0.1% SDS and 16SCC, 0.1% SDS, at 558C for 20 min each. They were exposed to X-ray ®lm at 7808C three overnight.
Mutation analysis of the h-neu transcript
Total RNA was extracted from normal brain tissues, Med-3 medulloblastoma cells, and 12 glioma cell lines (U87MG, U251MG, U138MG, Hs683, TG98, A172, SF126, U373MG, U105MG, NP1, NP2, RBR17T). cDNA synthesis was performed using 5 mg of total RNA incubated in a 20 ml volume reaction containing 50 mM Tris-HCL (pH8.3), 10 mM DTT, 10 mM KCl, 0.5 mM dNTP, 30 mg RNAsin (GIBCO, BRL), 150 mg superscript II reverse transcriptase (GIBCO, BRL) for 1 h at 378C. PCR reaction were performed with 2 ml of reverse transcriptase products in a 25 ml volume using rTth DNA polymerase per manufacturer instructions (Applied Biosystems) with a Perkin-Elmer Cetus Gene Amp PCR system 9600 (Norwalk, CT) for 30 cycles. To ensure successful completion of cDNA synthesis for each sample, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was ampli®ed with the following primers: GAPDHsens, 5'-AAGGCT-GGGGCTCATTTGCAG-3' and GAPDHanti 5'-CCAAA-TTCGTTGTCATACCAGG-3'.
We examined mutations of the entire coding region of hneu cDNA in glioma cell lines by performing direct sequencing of two overlapping PCR products. For amplification of the 5'-half of the h-neu cDNA, a set of primers (neuS-10.5: 5'-AGCTTCTGCAACGCCATCACCTT-3', neuAS-9.5: 5'-AAACGCAGGTC GCCGTCGAGCTG-3') was used. For ampli®cation of the 3'-half of the h-neu cDNA, another set of primers (neuS-13: 5'-AGCTGGTGCTCCCGGACTGTCTG-3', neuAS-stop: 5'-CTAGGAGCTGCGGTAGGTCTTGAT-3') was used. The direct DNA sequencing reactions of the PCR products were performed using a PRISM DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems) with AmpliTaq DNA polymerase and automated 373S DNA sequencer (Applied Biosystems).
To ensure nucleotide substitution at codon 253 of h-neu gene in U251MG cells, restriction fragment length analysis was performed using the RT ± PCR reaction followed by enzyme digestion of the ampli®ed products. For PCR, the 1071-bp fragment containing codon 253 was ampli®ed using primers neuS-13 (5'-AGCTGGTGCTCCCGGACTGTCTG-3') and neuAS-stop (5'-CTAGGAGCTGCGGTAGGTCTT-GAT-3'). The resulting amplicons were PvuII digested and analysed on 2% agarose gels.
